CA1065851A - Procede pour l'obtention du compose 17-alpha-ethinyl (5 alpha) 2-androstene 17 beta-ol a l'etat pur et applications therapeutiques du compose obtenu par ce procede - Google Patents
Procede pour l'obtention du compose 17-alpha-ethinyl (5 alpha) 2-androstene 17 beta-ol a l'etat pur et applications therapeutiques du compose obtenu par ce procedeInfo
- Publication number
- CA1065851A CA1065851A CA218,033A CA218033A CA1065851A CA 1065851 A CA1065851 A CA 1065851A CA 218033 A CA218033 A CA 218033A CA 1065851 A CA1065851 A CA 1065851A
- Authority
- CA
- Canada
- Prior art keywords
- alpha
- androstene
- beta
- ethinyl
- keto
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 24
- 230000008569 process Effects 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 7
- NTDNQJMXFXTZLE-FZFXZXLVSA-N (8s,9s,10s,13s,14s)-10,13-dimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CC2CC=CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 NTDNQJMXFXTZLE-FZFXZXLVSA-N 0.000 title description 8
- 230000001225 therapeutic effect Effects 0.000 title 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 239000000047 product Substances 0.000 claims abstract description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 6
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims abstract description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 5
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000011591 potassium Substances 0.000 claims abstract description 5
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 5
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims abstract 12
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims abstract 4
- 238000000605 extraction Methods 0.000 claims abstract 4
- 230000001590 oxidative effect Effects 0.000 claims abstract 4
- 239000011541 reaction mixture Substances 0.000 claims abstract 4
- 238000001953 recrystallisation Methods 0.000 claims abstract 4
- 239000007795 chemical reaction product Substances 0.000 claims abstract 3
- 239000003810 Jones reagent Substances 0.000 claims abstract 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 230000009471 action Effects 0.000 claims description 5
- 238000004440 column chromatography Methods 0.000 claims 2
- 239000000376 reactant Substances 0.000 claims 2
- NXQOQNROJJFYCJ-FZFXZXLVSA-N androst-16-ene Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CCC21 NXQOQNROJJFYCJ-FZFXZXLVSA-N 0.000 claims 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 abstract description 3
- 229940126657 Compound 17 Drugs 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 15
- 210000001672 ovary Anatomy 0.000 description 14
- 238000011282 treatment Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 229940011871 estrogen Drugs 0.000 description 9
- 239000000262 estrogen Substances 0.000 description 9
- 230000002611 ovarian Effects 0.000 description 7
- CGFFKDRVHZIQHL-UHFFFAOYSA-N 1-but-3-en-2-yl-3-(methylcarbamothioylamino)thiourea Chemical compound CNC(=S)NNC(=S)NC(C)C=C CGFFKDRVHZIQHL-UHFFFAOYSA-N 0.000 description 6
- 102000006771 Gonadotropins Human genes 0.000 description 6
- 108010086677 Gonadotropins Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229960003608 clomifene Drugs 0.000 description 6
- 239000002622 gonadotropin Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000016087 ovulation Effects 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 108090000445 Parathyroid hormone Proteins 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010062767 Hypophysitis Diseases 0.000 description 3
- 102100036893 Parathyroid hormone Human genes 0.000 description 3
- 241000218220 Ulmaceae Species 0.000 description 3
- 229940046836 anti-estrogen Drugs 0.000 description 3
- 230000001833 anti-estrogenic effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- 229960002568 ethinylestradiol Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001456 gonadotroph Effects 0.000 description 3
- 229940094892 gonadotropins Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000003635 pituitary gland Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 241000272814 Anser sp. Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 230000002710 gonadal effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000005644 metestrus Effects 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 230000000624 ovulatory effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000031968 Cadaver Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 241001175904 Labeo bata Species 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 102000004451 Pituitary Gonadotropins Human genes 0.000 description 1
- 108010081865 Pituitary Gonadotropins Proteins 0.000 description 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 206010036940 Prostatic adenoma Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- ZNZNXSDPNKCWNO-UHFFFAOYSA-N S.CO Chemical compound S.CO ZNZNXSDPNKCWNO-UHFFFAOYSA-N 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 230000000733 anti-osteolytic effect Effects 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 230000002054 antogonadotrophic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000026234 pro-estrus Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2211/74A GB1492746A (en) | 1974-01-17 | 1974-01-17 | Androstane derivatives and compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1065851A true CA1065851A (fr) | 1979-11-06 |
Family
ID=9735557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA218,033A Expired CA1065851A (fr) | 1974-01-17 | 1975-01-16 | Procede pour l'obtention du compose 17-alpha-ethinyl (5 alpha) 2-androstene 17 beta-ol a l'etat pur et applications therapeutiques du compose obtenu par ce procede |
Country Status (19)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3174614D1 (en) * | 1981-06-02 | 1986-06-19 | Theramex | Pharmaceutical compositions containing androstenes |
| JPS60173248A (ja) * | 1984-02-16 | 1985-09-06 | 三晃金属工業株式会社 | 嵌合外囲体 |
| JPS61503032A (ja) * | 1984-08-17 | 1986-12-25 | エス・ア−ル・アイ・インタ−ナシヨナル | 立体異性的に純粋な１７α−エチニル−エストラ−２−エン−１７β−オ−ルおよびその１７β−エステル、製造方法および用途 |
| US5116830A (en) * | 1984-08-17 | 1992-05-26 | Sri International | Stereoisomerically pure 17α-ethynyl-estra-2-en-17β-ol and the 17β esters thereof, methods of preparation and uses |
| DE3661832D1 (en) * | 1985-04-29 | 1989-02-23 | Theramex | Process for the preparation of pure androst-2-ene derivatives |
| FR2598083B1 (fr) * | 1986-05-05 | 1989-12-29 | Theramex Laboratoire | Nouvelles compositions pharmaceutiques a action antiprogesteronique et leur procede d'obtention |
| RU2652702C2 (ru) | 2016-10-19 | 2018-04-28 | Игорь Ву-Юнович Ван | Субатмосферная система теплохолодоснабжения |
-
1974
- 1974-01-17 GB GB2211/74A patent/GB1492746A/en not_active Expired
- 1974-12-18 CH CH1734774A patent/CH606091A5/xx not_active IP Right Cessation
- 1974-12-19 BE BE151716A patent/BE823594A/xx unknown
- 1974-12-30 DK DK690574AA patent/DK135538B/da not_active IP Right Cessation
- 1974-12-31 FR FR7443397A patent/FR2258185B1/fr not_active Expired
-
1975
- 1975-01-09 ES ES433677A patent/ES433677A1/es not_active Expired
- 1975-01-13 DE DE19752501091 patent/DE2501091A1/de active Pending
- 1975-01-14 JP JP698075A patent/JPS576439B2/ja not_active Expired
- 1975-01-14 ZA ZA00750254A patent/ZA75254B/xx unknown
- 1975-01-15 AU AU77335/75A patent/AU521392B2/en not_active Expired
- 1975-01-16 PH PH16719A patent/PH15366A/en unknown
- 1975-01-16 CA CA218,033A patent/CA1065851A/fr not_active Expired
- 1975-01-16 IT IT19319/75A patent/IT1044268B/it active
- 1975-01-16 LU LU71662A patent/LU71662A1/xx unknown
- 1975-01-16 SE SE7500479A patent/SE7500479L/xx unknown
- 1975-01-17 BR BR346/75A patent/BR7500346A/pt unknown
- 1975-01-17 AR AR257331A patent/AR203672A1/es active
- 1975-01-17 NL NLAANVRAGE7500608,A patent/NL183402C/xx not_active IP Right Cessation
- 1975-01-17 IE IE83/75A patent/IE40477B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BE823594A (fr) | 1975-04-16 |
| PH15366A (en) | 1982-12-10 |
| DE2501091A1 (de) | 1975-07-24 |
| LU71662A1 (enrdf_load_stackoverflow) | 1975-06-24 |
| ES433677A1 (es) | 1976-11-16 |
| GB1492746A (en) | 1977-11-23 |
| FR2258185B1 (enrdf_load_stackoverflow) | 1978-07-28 |
| IE40477L (en) | 1975-07-17 |
| DK135538B (da) | 1977-05-16 |
| BR7500346A (pt) | 1975-11-04 |
| AU7733575A (en) | 1976-07-15 |
| NL183402C (nl) | 1988-10-17 |
| SE7500479L (enrdf_load_stackoverflow) | 1975-07-18 |
| NL7500608A (nl) | 1975-07-21 |
| IT1044268B (it) | 1980-03-20 |
| JPS50106952A (enrdf_load_stackoverflow) | 1975-08-22 |
| NL183402B (nl) | 1988-05-16 |
| IE40477B1 (en) | 1979-06-06 |
| JPS576439B2 (enrdf_load_stackoverflow) | 1982-02-04 |
| FR2258185A1 (enrdf_load_stackoverflow) | 1975-08-18 |
| AU521392B2 (en) | 1982-04-01 |
| DK135538C (enrdf_load_stackoverflow) | 1977-10-24 |
| DK690574A (enrdf_load_stackoverflow) | 1975-09-29 |
| AR203672A1 (es) | 1975-09-30 |
| CH606091A5 (enrdf_load_stackoverflow) | 1978-10-13 |
| ZA75254B (en) | 1976-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aoki et al. | Is there a local feedback from the seminiferous tubules affecting activity of the Leydig cells? | |
| CN106083969B (zh) | 合成胆汁酸组合物、方法和制剂 | |
| DE69901250T2 (de) | 7.alpha.-methyl 19-nortestosteron undecanoat mit androgenischer aktivität | |
| CA1065851A (fr) | Procede pour l'obtention du compose 17-alpha-ethinyl (5 alpha) 2-androstene 17 beta-ol a l'etat pur et applications therapeutiques du compose obtenu par ce procede | |
| JP2003510336A (ja) | 虚血性損傷においてのエストロゲンのエナンチオマーを用いる細胞保護の方法 | |
| AU2008323198B2 (en) | C-19 steroids for cosmetic and further uses | |
| EP2949361B1 (en) | C-19 steroids for treating cellulite | |
| US20100173883A1 (en) | 7-hydroxyepiandrosterone having neuroprotective activity | |
| Ahluwalia et al. | Effects of exogenous hormones on the male reproductive organs of vitamin A-deficient rats | |
| AU2001267709A1 (en) | 7-hydroxyepiandrosterone having neuroprotective activity | |
| DE69126622T2 (de) | 2beta,19-methylenamin überbrückte steroide als aromatasehemmer | |
| Szabó et al. | Ultrastructural localisation of adrenal cholesterol by autoradiography and digitonin reaction after cycloheximide-induced inhibition of corticosterone synthesis | |
| Somade et al. | Effect of edible camphor administrations on levels of steroid and thyroid hormones in male wistar rats | |
| FR2417M (enrdf_load_stackoverflow) | ||
| Chung et al. | Testicular lipids in mice with testicular feminization | |
| CA1140111A (fr) | PROCEDE DE PREPARATION D'UN NOUVEAU DERIVE DU (20S) 3.alpha.- /(AMINO-ACETYL)AMINO/ 5.alpha.-PREGNAN-20-OL ET DE SES SELS | |
| RU2066184C1 (ru) | Средство для лечения себореи и угревой сыпи | |
| EP0240717A2 (en) | Prevention of mammary carcinoma | |
| WO2025008804A1 (en) | Combination therapy for amelioration of side effects of estrogen receptor inhibitor treatment | |
| DE60210268T2 (de) | Verfahren zur herstellung von 7alpha,11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one, dessen 17-ester und pharmazeutische zubereitungen die sie enthalten | |
| JPH07252146A (ja) | 副腎皮質ホルモン産生促進剤 | |
| Ota et al. | Inhibition of testicular androgenesis by urinary gonadotropin-inhibiting substances in rats | |
| CH616690A5 (en) | Process for the preparation of a new alkoxylated steroid |